Abciximab (c7E3 Fab, ReoPro), a platelet glycoprotein (GP) IIb/IIIa inhibitor, decreases acute @entity63 complications after percutaneous coronary interventions. Recently, abciximab was shown to decrease thrombin generation in vitro in a static system. To assess whether abciximab can decrease fibrin formation in blood from @entity1 , we quantified both platelet thrombi and fibrin deposition by using an ex vivo flow chamber model. We prospectively studied 18 consecutive @entity1 who underwent percutaneous interventions for unstable coronary syndromes. Blood was perfused directly from the @entity1 through an ex vivo perfusion chamber at a high shear rate, thus mimicking mildly stenosed coronary arteries. Perfusion chamber studies were performed when @entity1 were being treated with heparin plus @entity117 before the procedure (baseline) and then repeated after the procedure, when @entity1 were on either @entity117 plus heparin alone (group 1, no abciximab, control) or @entity117 plus heparin plus abciximab (group 2, abciximab treated). Each @entity1 served as his or her own control. Specimens were stained with combined Masson's trichrome-elastin and antibodies specific for @entity2002 , fibrin, and platelet @entity1428 . Total @entity715 area and areas occupied by platelet aggregates and fibrin layers were quantified by planimetry. Group 1 demonstrated no significant change in @entity715 area before versus after the procedure; in contrast, treatment with abciximab reduced total @entity715 area by 48% in group 2 (after the procedure versus baseline, P=0.01). This decline was due to significant @entity1423 (55%, P=0.005) and fibrin layers (45%, P=0.03). The addition of abciximab to heparin and @entity117 in @entity1 undergoing coronary interventions significantly decreases ex vivo @entity715 formation on an injured vascular surface. Treatment with abciximab appears to reduce both the platelet and the fibrin @entity715 components. This finding supports a potential role for @entity1427 /IIIa receptor blockade in decreasing fibrin formation in addition to inhibition of @entity1423 . Thus, potent inhibitors of @entity1427 /IIIa may also act as anticoagulants.

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo XXXX formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['reductions in both platelet aggregates', 'platelet aggregation'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1428 :: ('3690', 'Gene') :: ['GP IIIa'] @entity1427 :: ('3674', 'Gene') :: ['GP IIb'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']
@entity1423 :: (MESH:D001791,Disease) :: ['platelet thrombus']
